Local Tech Wire

RALEIGH, N.C. – BioDelivery Sciences International (Nasdaq: BDSI) has signed a licensing deal for its new breakthrough pain reliever with a South Korean firm.

BDSI receives a $300,000 upfront payment as well as milestones that could be worth nearly $1 million more from Kunwha Pharmaceutical for licensing and supply agreements to Onsolis.
The U.S. Food and Drug Administration approved Onsolis last July.

BDSI is also seeking approval to sell the powerful drug in Europe.

A patch that delivers an opiate pain killer, Onsolis is designed to dissolve in a patient’s cheek.

For details,

Get the latest news alerts: at Twitter.